Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, ...

The White House’s budget request proposes a nearly $18 billion cut to NIH spending, and nearly $4 billion slashed at the CDC.

Aera Therapeutics shifts focus to lipid nanoparticles for T-cell targeting therapy while continuing work on protein ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

Flagship Pioneering has recruited Rahul Kakkar to lead its genetics-based drug discovery startup Quotient Therapeutics.

Aviva Capital Partners & Socius plan £1B cancer research hub in Sutton, UK, near Institute of Cancer Research & Royal Marsden ...

FDA delays Cytokinetics' aficamten PDUFA date to Dec 26 after company adds REMS to heart disease drug application; stock down ...

While Pfizer recently pulled the plug on its most advanced obesity candidate, Amgen has moved its own key weight loss play ...

FDA advisors next week will discuss the risks of long-term opioid use during a joint-committee meeting that will examine two ...

Bristol Myers Squibb closing viral vector site in Libertyville, IL, shifting production to Devens, MA; affects workers from ...

Moderna tried to assuage investors Thursday that enhanced scrutiny of its vaccines in the US wouldn’t hamper its progress.

Amicus pays Dimerix $30M upfront for US rights to DMX-200, a late-stage FSGS therapy, with potential milestone payments of ...